# A Study of LY4515100 in Healthy Participants

> **NCT07339722** · PHASE1 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 40 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY4515100 via SAD
- **DRUG:** LY4515100 via MAD

## Key facts

- **NCT ID:** NCT07339722
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07339722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07339722, "A Study of LY4515100 in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07339722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*